1990
2000
2010
2015
~10–12
~8–10
~6–8
~12+
1994
Vinorelbine
Median OS, months
1996–99
Platinum-based doublet
2001
Docetaxel +
chemotherapy
2006
Bevacizumab + chemotherapy: NSQ
2008
Pemetrexed + chemotherapy: NSQ
a
Median OS >20 months
with targeted therapies
for patients with
EGFR
mutations or
ALK
translocation
2012
Nab-paclitaxel
+ chemotherapy
~10–12
~8–10
~6–8
~12+
Median OS, months
2004
Erlotinib
1999
Docetaxel
2004
Pemetrexed: NSQ
2014
Nintedanib + docetaxel: NSQ
a
2015
Nivolumab: SQ
2014
Ramucirumab + docetaxel
2015
Nivolumab: NSQ
NSCLC: OS improvements
Pretreated
1
st
-line
a
Adenocarcinoma only. ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer; NSQ=non-squamous; OS=overall survival;
SQ=squamous.
Stinchcombe TE, F1000Prime Rep. 2014;6:117; Giotrif US Prescribing Information; Alimta US Prescribing Information; Avastin US Prescribing Information; Taxotere US Prescribing
Information; Tarveva US Prescribing Information; Socinski MA, et al.
J Clin Oncol.
2012;30:2055–2062; Opdivo US Prescribing Information; Cyramza US Prescribing Information; Vargatef
SmPC; Paz-Ares L, et al. Presented at ASCO 2015, Abstract LBA109; Schiller J, et al.
New Engl J Med.
2002;346:92–98.
2015
Pembrolizumab: PD-L1 +
2016
Pembrolizumab: PD-L1 > 50%
2016
2016
Atezolizumab
